Envista Holdings Corporation

Envista Holdings Corporation

24.03
USD
-0.46
(-1.88%)
3.84EPS
6.03P/E
3.76BMarket Cap
Feb 10Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
18.02
18.18
18.4
16.78
12.09
15.56
15.77
15.38
14.58
16.19
17.68
Basic EPS, GAAP
1.76
1.95
1.49
1.6
0.21
2.11
1.49
-0.6
-6.5
0.28
3.89
Free Cash Flow per Basic Share
2.38
2.01
2.12
2.35
1.48
1.9
0.66
1.3
1.76
1.37
1.49
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
32.27
31.19
22.31
23.25
25.11
25.78
24.34
17.04
18.96
19.27
Tangible Book Value per Share
- -
0.68
0.69
-6.63
-4
-0.75
-2.31
-0.42
0.13
0.74
0.95
Basic Weighted Avg Shares
155
155
155
136
160
161
163
167
172
168
163
Sales/Revenue/Turnover
2,785
2,811
2,845
2,285
1,929
2,509
2,569
2,567
2,511
2,720
2,878
Operating Margin (%)
14.46
13.75
10.49
10.32
2.25
12.2
13.36
12.27
5.46
8.67
11.35
Depreciation Expense
127
121
130
168
163
152
162
163
155
151
148
Net Income, GAAP
272
301
231
218
33
341
243
-100
-1,119
47
634
Effective Tax Rate (%)
32.29
22.14
23.38
21.22
- -
- -
16.17
- -
- -
73.48
7.42
Profit Margin (%)
9.77
10.71
8.11
9.52
1.73
13.57
9.46
-3.9
-44.56
1.73
22.01
Working Capital
- -
166
146
293
-94
628
188
963
910
1,174
1,186
LT Debt
- -
- -
- -
1,507
1,060
1,004
992
1,508
1,397
1,559
1,550
Total Equity
- -
4,995
4,826
3,543
3,721
4,058
4,207
4,174
2,935
3,106
3,089
Return on Invested Capital (%)
- -
- -
4.66
3.75
- -
- -
4.73
- -
- -
1.24
14.28
Return on Capital (%)
- -
- -
4.7
4.45
- -
- -
4.89
- -
- -
1.23
14.21
Return on Common Equity (%)
- -
- -
4.7
5.2
0.92
8.76
5.88
-2.39
-31.47
1.56
20.52

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
39
39
38
LT Borrowings
1,439
1,436
1,429
LT Finance Leases
111
113
121
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
163
161
160
Market Capitalization
4,133
4,232
3,762

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,919
1,958
2,002
Cash, Cash Equivalents & STI
1,083
1,126
1,159
Accounts Receivable, Net
437
437
449
Inventories
300
291
285
Total Current Liabilities
787
807
816
Payables & Accruals
238
250
237
ST Debt
39
39
38
Deferred Revenue
188
192
189

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2.38%
5.84%
Free Cash Flow
- -
16.67%
-23.89%
Net Income, GAAP
- -
332.97%
-104.2%
Sales/Revenue/Turnover
- -
7.7%
8.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
624
633
601
653
2,511
2025
617
682
670
751
2,720
2026
706
731
692
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
-6.69
0.05
0.01
-6.5
2025
0.1
0.16
-0.18
0.2
0.28
2026
0.24
0.33
3.16
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Paul A. Keel
Full Time Employees
12,000
Sector
Health technology
Industry
Medical specialties
Address
Building E Brea CA United States 92821-6208
IPO Date
Sep 18, 2019
Business
Envista Holdings Corp (NYSE: NVST) develops and manufactures a broad portfolio of dental products and technologies for dental professionals worldwide. The company operates through two primary segments: Specialty Products & Technologies, which offers dental implant systems, prosthetics, clear aligners, brackets and wires, orthodontic and laboratory products; and Equipment & Consumables, which provides digital imaging systems, dental practice equipment, endodontic systems, restorative and impression materials, bonding agents and cements, and infection prevention products. Envista serves dental offices, orthodontists, oral surgeons, and laboratories with innovative solutions supporting integrated digital workflows, training programs, and comprehensive patient care tools across more than 120 countries. Founded in 2019 as a spin-off from Danaher Corp and headquartered in Brea, California, the company encompasses over 30 trusted brands with more than 125 years of combined industry heritage. In June 2025, Envista acquired Alpha-Bio France to strengthen its implant and prosthetics offerings in Europe; the company continues strategic mergers and acquisitions to expand its global reach and technological capabilities, anchored by the Envista Business System for operational excellence.

Company News

  • Here's Why You Should Retain NVST Stock in Your Portfolio for Now

  • Why Envista (NVST) is a Top Value Stock for the Long-Term

  • Envista Announces Pricing of $430 Million of Senior Notes

  • Envista (NVST) is a Top-Ranked Momentum Stock: Should You Buy?

  • Envista Q3 Earnings Call Highlights '26 Guidance Raise & China Risks

  • What Envista (NVST) Said on Its Q3 Earnings Call

  • Envista Holdings Corporation (NVST) Q3 2026 Earnings Call Transcript

  • Envista (NVST) Reports Q3 Earnings: What Key Metrics Have to Say

  • Envista (NVST) Tops Q3 Earnings and Revenue Estimates

  • Envista Reports Third Quarter 2026 Results

  • Envista Q3 Earnings Ahead: Product Innovation to Drive Growth

  • Envista (NVST) Earnings Expected to Grow: Should You Buy?

  • Envista Announces Release of 2025 Sustainability Report

  • Reviewing MariMed (OTCMKTS:MRMD) and Envista (NYSE:NVST)

  • Envista Holdings Corporation (NYSE:NVST) Stock Rated “Hold” by Wall Street Brokerages

  • Envista (NVST) is a Top-Ranked Value Stock: Should You Buy?

  • Here's Why Envista (NVST) is a Strong Growth Stock

  • Recently Appointed Cooper Companies Director Paul Keel Buys $250,000 Stock. Does This Signal Shares are a Buy?

  • Envista Schedules Third Quarter 2026 Earnings Call

  • New Strong Buy Stocks for September 28th